On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...

On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe ...

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...

Beam Therapeutics (NASDAQ:BEAM) shared promising results from the early stage trial of its genetically modified cell therapy, BEAM-101, for the treatment of severe sickle cell disease. The data ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 ...

Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...